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In the development of new drugs as well as new formula-
tions of existing products (including generic products), it is of
great interest to be able to predict to what extent the drug can
be absorbed from the gastrointestinal (GI) tract and how the
formulation and dosing conditions may affect the absorption
profile.The hypothesis behind Biorelevant release testing is that
“the closer the test conditions can simulate the gastrointes-
tinal environment, the better the prediction will be.” Typical
aspects of GI physiology, which can influence drug
bioavailability, are the composition of the GI fluids (which affects
various processes including release from the dosage form and
stability of the drug), GI motility and hydrodynamics (transit
characteristics of the dosage form, release from the dosage form
etc.), and permeability of the GI mucosa to the drug as a func-
tion of location in the GI tract, and gut wall metabolism.While
release from the dosage form can be addressed with Biorelevant
release tests, which seek to reproduce compositional and hy-
drodynamic conditions at various locations within the GI tract,
the interplay of release with gut wall permeability, gastric emp-
tying and first pass metabolism are difficult to reflect in these
in vitro release tests. By coupling the release test results with
a physiologically based pharmacokinetic (PBPK) model that
details GI physiology as well as post absorptive events in the
body, there is great value added in terms of predicting in vivo
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performance of the drug. This presentation will highlight the
physiological conditions in the GI tract relevant to drug and
formulation performance in the fasted and fed states, de-
scribe the Biorelevant release test conditions that can be used
to simulate these and show two case examples (both poorly
soluble weak bases) where coupling Biorelevant release testing
with PBPK modelling has successfully predicted plasma pro-
files of the drug after oral administration.
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Fig. 1 – The Berlin Decision Tree for development of poorly soluble weak bases (with copyright permission from M. Berlin).
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